HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Sign In to gain access to subscriptions and/or personal tools.

This Article Full Text Free Full Text (PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (8) Citing Articles via Google Scholar Google Scholar Articles by Kalus, J. S. Articles by White, C. M. Search for Related Content PubMed PubMed Citation Articles by Kalus, J. S. Articles by White, C. M.

The Impact of Suppressing the Renin-Angiotensin System on Atrial Fibrillation

From Wayne State University, Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, Michigan (Dr Kalus); Henry Ford Hospital, Department of Pharmacy Services, Detroit, Michigan (Dr Kalus); University of Connecticut, School of Pharmacy, Storrs (Dr Coleman, Dr White); and Hartford Hospital, Department of Pharmacy, Hartford, Connecticut (Dr Coleman, Dr White).

Atrial fibrillation is very common in the United States. After a search of Medline, EMBASE, and CINAHL, 4 trials evaluating inhibitors of the renin-angiotensin system were identified for prevention of new-onset atrial fibrillation, facilitation of electrical cardioversion of atrial fibrillation, and prevention of atrial fibrillation recurrence after electrical cardioversion. A meta-analysis was performed using a random-effects model. Use of an angiotensin-converting enzyme (ACE) inhibitor or angiotensin-receptor blocker (ARB) was associated with a reduction in new-onset atrial fibrillation (OR [95% CI] = 0.51 [0.36-0.72]), a lower failure rate of electrical cardioversion of atrial fibrillation (0.47 [0.24-0.92]), and a lower rate of recurrence of atrial fibrillation after electrical cardioversion (0.39 [0.20-0.75]). With the exception of the new-onset atrial fibrillation analysis, these findings were not associated with statistical heterogeneity. These hypothesis-generating data suggest that inhibitors of the renin-angiotensin system may provide benefit across the spectrum of atrial fibrillation.

Key Words: Atrial fibrillation • angiotensin-converting enzyme inhibitor • angiotensin receptor antagonist • systematic review

Address for reprints: James S. Kalus, PharmD, BCPS, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, 259 Mack Avenue, Suite 2190, Detroit, MI 48201.

This article has been cited by other articles:

				C. M. White, J. Kluger, K. Lertsburapa, O. Faheem, and C. I. Coleman Effect of preoperative angiotensin converting enzyme inhibitor or angiotensin receptor blocker use on the frequency of atrial fibrillation after cardiac surgery: a cohort study from the atrial fibrillation suppression trials II and III Eur. J. Cardiothorac. Surg., May 1, 2007; 31(5): 817 - 820. [Abstract] [Full Text] [PDF]

				C. I Coleman, S. Makanji, J. Kluger, and C M. White Effect of Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers on the Frequency of Post-Cardiothoracic Surgery Atrial Fibrillation Ann. Pharmacother., March 1, 2007; 41(3): 433 - 437. [Abstract] [Full Text] [PDF]

				N. Guler, C. Ozkara, H. Dulger, V. Kutay, M. Sahin, E. Erbilen, and H. A. Gumrukcuoglu Do Cardiac Neuropeptides Play a Role in the Occurrence of Atrial Fibrillation After Coronary Bypass Surgery? Ann. Thorac. Surg., February 1, 2007; 83(2): 532 - 537. [Abstract] [Full Text] [PDF]